Background: despite its vast utility in clinical oncology, the use of doxorubicin is limited by a
potentially fatal cardiomyopathy and congestive heart failure. Free radical formation and …

Doxorubicin (DOX) is the most effective and frequently used anticancer drug. This work
aimed to study the protective role of silymarin (SIL) against DOX induced cardiotoxicity. Forty …

Silymarin is a complex of five major compounds, and silibinin is the most biologically active
component of the complex. The aim of this study was to investigate, evaluate and confirm the …

Background Doxorubicin (DOX) is a potent chemotherapeutic agent used in the treatment of
several tumors but its cardiac toxicity prevents its use at a maximum dose, representing an …

Purpose Although doxorubicin chemotherapy is commonly applied for treating different
malignant tumors, cardiotoxicity induced by this chemotherapeutic agent restricts its clinical …

Aim: Doxorubicin, a widely used antineoplastic agent in clinical practice, has a serious side
effect, cardiotoxicity. Due to the risk of life-threatening cardiotoxicity which limits the …

Background Several mechanisms have been explored for the anthracycline myocardial
toxicity. These are free-radical generation, myocyte apoptosis, lipid peroxidation …

The usefulness of doxorubicin (DOX), a highly effective antitumor drug, is limited by the risk
of developing cardiomyopathy. Subcellular changes leading to this toxicity are suggested to …

Doxorubicin is useful anticancer drug because it's used in treatment of acute leukemia,
Hodgkin's and non-Hodgkin's lymphomas, and many other malignant neoplasm. The …

Abstract Context: Doxorubicin (Dox) is one of the most active chemotherapeutic agents used
to treat various types of cancers. Its clinical utility is compromised due to fatal cardiac toxicity …